Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01730092 · ClinicalTrials.gov registry record
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
A clinical trial of Pulmonary Hypertension and Pulmonary Disease, sponsored by National Institutes of Health Clinical Center (CC).
- Recruiting
- Registry status
- 270
- Enrollment target
- 1
- Study location
NCT01730092: Recruiting study of Pulmonary Hypertension and Pulmonary Disease, sponsored by National Institutes of Health Clinical Center (CC).
NCT01730092 is a study of Pulmonary Hypertension and Pulmonary Disease that is actively recruiting participants, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 270 participants, below the 610-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01730092, a study of Pulmonary Hypertension and Pulmonary Disease, is actively recruiting participants, sponsored by National Institutes of Health Clinical Center (CC).
- RECRUITING
- Registry status
- 270 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause. Researchers want to follow the natural history of all PAH patients to understand how PAH progresses in order to discover targets for future research into new treatments. To further identify treatment targets, they will compare healthy volunteers to patients with PAH. Objectives: \- To study the natural history of PAH. Eligibility: * Individuals at least 18 years of age who have PAH. * Healthy volunteers at least 18 years of age. Design: * Participants with PAH will have periodic visits to the National Institutes of Health Clinical Center. After the first visit, they will return in 6 months and then yearly or every other year for as long as the study continues. * The first visit will take up to 3 days. It will involve the following tests: * Physical exam and medical history * Blood and urine samples * Heart and lung function tests and imaging studies * Six-minute walk test * Questions about exercise and physical activity * Healthy volunteers will have only one visit to the Clinical Center, during which they will undergo screening tests, and complete many of the same tests as patients with PAH
Primary Outcome
Compare outcomes in PAH subjects with controls
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2013-07-15 |
What NCT01730092 shows while recruiting
NCT01730092 is an observational study that tracks outcomes without assigning an intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 610-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (56% lower).
The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 0 interventions.
NCT01730092 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01730092 about?
NCT01730092 is a clinical study titled "Natural History Study of Biomarkers in Pulmonary Arterial Hypertension". Background: \- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause. Researchers want to follow the natural history of all PAH patients to understand how PAH progresses i...
What is the current status of trial NCT01730092?
This trial is currently recruiting. The enrollment target is 270 participants. The study started on 2013-07-15.
What conditions does trial NCT01730092 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Pulmonary Disease.
Who is sponsoring clinical trial NCT01730092?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01730092 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01730092's enrollment target sits among peer trials
270 17th of 72 higher than 56 of 72 other Pulmonary Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
RECRUITING
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders
RECRUITING
-
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
RECRUITING · Phase 3
-
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI